Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

The Effect of SRS on Hemiplegia in Stroke Survivors

NCT: NCT06357247 · SUSPENDED

NCT IDNCT06357247
StatusSUSPENDED
Start Date2024-03-04
Completion2027-02

Brief Summary

Strokes are one of the leading causes of long term disability and death in the United States. A stroke occurs when the blood supply to the brain is blocked, damaging parts of the brain. Many stroke survivors have difficulty completing dexterous hand movements and manipulating objects due brain damage in the sensorimotor cortex. Damage to these areas can cause decreased motor movements and tactile sensation on the affected side. Research shows that tactile sensation is necessary for maintaining grip, grading grip forces and decreasing object slippage. Therefore, it is important to address tactile sensation with motor performance during stroke rehabilitation to improve performance outcomes among stroke survivors.

Frequently Asked Questions

What is The Effect of SRS on Hemiplegia in Stroke Survivors?

The Effect of SRS on Hemiplegia in Stroke Survivors is a clinical trial registered under NCT06357247. Current status: SUSPENDED.

What is the status of NCT06357247?

The current status of NCT06357247 (The Effect of SRS on Hemiplegia in Stroke Survivors) is: SUSPENDED.

When did The Effect of SRS on Hemiplegia in Stroke Survivors start?

The Effect of SRS on Hemiplegia in Stroke Survivors started on 2024-03-04.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.